Press Release: Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results
Press Release: Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results
Press Release: Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results
新聞稿：彪馬生物技術公司將主持電話會議，討論2020年第四季度和全年財務業績
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results
彪馬生物技術公司將主持電話會議，討論2020年第四季度和全年財務業績
LOS ANGELES--(BUSINESS WIRE)--February 11, 2021--
洛杉磯--(美國商業新聞網)--2021年2月11日--
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 25, 2021, following release of its fourth quarter and full year 2020 financial results.
彪馬生物技術公司(納斯達克市場代碼：PBYI)是一家生物製藥公司，該公司將於美國東部時間下午1：30主持電話會議。太平洋標準時間/下午4：30美國東部時間2021年2月25日(星期四)，在發佈2020年第四季度和全年財務業績後。
The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma's website for 90 days.
撥打1-877-709-8150(國內)或1-201-689-8354(國際)可撥打該電話。請至少提前10分鐘撥打電話，並通知接線員您想參加“彪馬生物技術電話會議”。電話會議和演示幻燈片的現場網絡直播可以在彪馬生物技術公司網站的投資者欄目上獲得，網址是：http://www.pumabiotechnology.com.。電話會議的重播將在通話結束大約一小時後播放，並將在彪馬的網站上存檔90天。
About Puma Biotechnology
關於彪馬生物技術
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX(R) (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
彪馬生物技術公司是一家生物製藥公司，專注於創新產品的開發和商業化，以加強癌症治療。彪馬In-授權PB272(口服奈拉替尼)、PB272(奈拉替尼靜脈注射)和PB357的全球開發和商業化權利。在基於曲妥珠單抗的輔助治療之後，neratinib口服於2017年被美國食品和藥物管理局(FDA)批准用於HER2過度表達/放大的早期乳腺癌成年患者的擴展輔助治療，並在美國以NERLYNX(R)(Neratinib)片劑的形式銷售。2020年2月，NERLYNX還被FDA批准與卡培他濱聯合用於治療晚期或轉移性HER2陽性乳腺癌的成年患者，這些患者之前在轉移環境中接受了兩種或兩種以上基於HER2的抗化療方案。NERLYNX於2018年獲得歐盟委員會的營銷授權，可以延長對患有早期激素受體陽性HER2過度表達/放大的乳腺癌的成年患者的輔助治療，這些患者距離之前完成基於曲妥珠單抗的輔助治療不到一年。NERLYNX是彪馬生物技術公司的註冊商標。
Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.
欲瞭解有關彪馬生物技術公司的更多信息，請訪問網站www.PumabioTechnology.com。
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005729/en/
在business wire.com上查看源代碼版本：https://www.businesswire.com/news/home/20210211005729/en/
CONTACT: Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
聯繫人：彪馬生物技術公司艾倫·H·奧爾巴赫(Alan H.Auerbach)或瑪麗安·奧哈尼辛(Mariann Ohanesian)電話：+1 424 248 6500
info@pumabiotechnology.com
郵箱：info@pumabiotechnology ology.com
ir@pumabiotechnology.com
郵箱：ir@umabioTechnology.com
David Schull or Maggie Beller, Russo Partners, +1 212 845 4200
Russo Partners公司大衞·舒爾或瑪吉·貝勒電話：+1212845 4200
david.schull@russopartnersllc.com
郵箱：david.schull@russopartnersllc.com
maggie.beller@russopartnersllc.com
郵箱：maggie.beller@russopartnersllc.com
(END) Dow Jones Newswires
(完)道瓊通訊社
February 11, 2021 16:29 ET (21:29 GMT)
2021年2月11日美國東部時間16：29(格林尼治標準時間21：29)
譯文內容由第三人軟體翻譯。